#Japan #Tokyo #Psoriasis #AbbVie #Skyrizi

Introduction

AbbVie, a leading global biopharmaceutical company, has announced that it has received regulatory approval for its biologic therapy, Skyrizi (risankizumab), for the treatment of pediatric patients over six years old suffering from moderate to severe forms of psoriasis and related conditions. This new indication addresses long-standing unmet needs in the management of psoriasis in children.

Background on Skyrizi

Skyrizi is a humanized monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a key cytokine involved in inflammatory processes associated with psoriasis. Initially approved for adult patients in March 2019, Skyrizi has shown significant efficacy in treating chronic plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis. The recent approval enhances the scope of its use in pediatric populations, promoting a more comprehensive treatment approach for young patients.

Implications of the New Approval

The newly granted approval allows Skyrizi to be administered to pediatric patients with treatment-resistant moderate to severe psoriasis, as well as psoriatic arthritis and other associated inflammatory conditions. With this approval, AbbVie introduces a new 55mg prefilled syringe, enhancing dosing versatility, particularly for children weighing less than 40kg. The initial and follow-up doses for children will vary based on weight, ensuring tailored treatment for diverse populations.

The Need for Pediatric Psoriasis Treatments

Psoriasis is a chronic inflammatory skin disease characterized by the presence of raised, red patches of skin covered with silvery scales. In Japan, psoriasis affects an estimated 430,000 individuals, with pediatric cases constituting around 0.8% in ages 0-9 and 1.8% in ages 10-19. The visibility of psoriasis can lead to stigmatization, adversely impacting the quality of life for young patients, affecting their social interactions and educational pursuits.

Moreover, pediatric patients often face additional health challenges, including obesity, dyslipidemia, hypertension, and mental health issues such as anxiety and depression. The lack of comprehensive treatment options specific to children underscores the importance of AbbVie's recent approval, which aims to expand treatment avenues and improve the overall outcomes for pediatric psoriasis sufferers.

Statements from AbbVie leadership

Tiago Campos Rodriguez, President of AbbVie Japan, emphasized the significance of this approval, stating, "The addition of pediatric indications for Skyrizi is a beacon of hope for children and families dealing with psoriasis. By introducing a lighter dosing option with the 55mg prefilled syringe, we can better cater to diverse treatment needs. AbbVie remains committed to delivering innovative solutions for those battling autoimmune skin diseases."

Clinical Evidence Supporting the Approval

The approval is grounded in findings from international Phase 3 trials (M19-977 and M19-973), which demonstrated the effectiveness of Skyrizi in treating moderate-to-severe pediatric plaque psoriasis. These trials emphasized not only the drug's efficacy but also its safety profile in younger patients, further validating AbbVie's approach to expand access and treatment options for pediatric populations.

Conclusion

Efforts to address the unmet needs of pediatric psoriasis patients are increasingly important, and the approval of Skyrizi presents a promising development in dermatological care. As AbbVie continues to work on innovative treatment solutions, the availability of Skyrizi enhances the therapeutic landscape for children suffering from this challenging condition. By offering a new treatment avenue, AbbVie aims to improve the life quality of pediatric patients afflicted with psoriasis, paving the way for specialized care in this vulnerable demographic.